Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
Arm 1 (Criteria-Fulfilled group):
- People aged 18 to 79 years old at the time their cancer came back.
- People with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has come back for the first time and responded to platinum-based chemotherapy, meaning treatment ended at least 6 months before the cancer returned.
- If the person previously took a PARP inhibitor (a type of targeted cancer drug) as maintenance therapy, the cancer must have started progressing at least 3 months after stopping that drug.
- The person's cancer does not have BRCA1 or BRCA2 gene mutations (neither inherited nor acquired in the tumour).
- A test result for Homologous Recombination Deficiency (a measure of DNA repair in cancer cells) must be available (confirm with trial site).
- The person must be able to provide stored or freshly collected tumour tissue samples for testing.
- The tumour must test positive for a protein called PD-L1 (found on at least 1% of tumour cells or at least 5% of nearby immune cells), and there must be at least 6 immune cells called CD8+ T cells visible in a standard microscope view of the tumour.
- Experienced surgeons must assess that all visible returning cancer can be completely removed, based on a scoring tool or a PET/CT scan.
- The person must have a general health and activity level rated 0 to 2 on a standard scale (meaning able to carry out daily activities, with or without some limitations).
- Bone marrow, liver, and kidney function must be adequate enough to receive combination immunotherapy treatment.
- The person must provide written agreement to participate in the trial.
Arm 2 (Compassionate Use group):
- Similar criteria to Arm 1, with two differences: if the person previously took a PARP inhibitor, the cancer may have progressed within 3 months of stopping it, or even while still taking it.
- The PD-L1 or CD8+ T cell criterion is slightly broader — either the tumour tests positive for PD-L1, or there are at least 6 CD8+ T cells per microscope view (rather than requiring both).
Arm 3 (Real-World group):
- People who meet the inclusion criteria for Arm 1 or Arm 2 but choose not to participate in those study groups.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer is a borderline tumour, low-grade tumour, clear cell carcinoma, or a non-epithelial type of tumour.
- People whose cancer has not responded to platinum-based chemotherapy, or whose cancer continued growing during that treatment.
- People for whom no tumour tissue samples (stored or recently collected) are available for testing.
- People who have previously received immunotherapy treatment.
- People who have received a live vaccine or any anti-cancer treatment within 4 weeks before the first dose in this trial.
- People who have or have had another separate cancer within the past 5 years, or who have other cancer spread that requires treatment at the same time — except for certain early-stage cancers such as carcinoma in situ or breast cancer with no signs of returning.
- People who have cancer that has spread into organ tissue (parenchymal metastases) and who face serious life-threatening complications in the short term.
- People with other medical conditions that would make surgery, chemotherapy, or immunotherapy unsafe or prevent them from following the trial plan.
- People with a known allergy to Sintilimab (the immunotherapy drug used in this trial) or any of its ingredients.
- People for whom a Homologous Recombination Deficiency (HRD) test result is not available.
- People taking medications that significantly increase the risk of surgery — for example, blood thinners (oral anticoagulants) or bevacizumab, due to bleeding risk.
- People for whom the planned surgery is an interval debulking procedure, a second-look surgery, or palliative (comfort-focused) surgery.
- People for whom doctors are unable to assess whether the returning cancer can be surgically removed, or where imaging suggests complete removal would not be possible.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If this is close to home
This page includes language about advanced illness, prognosis, or palliative care, because that is how the trial's eligibility criteria are written. Seeing it set out plainly can land hard, whether it is about you or about someone you are caring for. You do not have to be at a crisis point to talk to someone.
- Griefline — grief and loss counselling, 9am to 6pm weekdays and midday to 6pm weekends (AEST/AEDT): 1300 845 745
- Carer Gateway — practical and emotional support if you are caring for someone, 8am to 5pm weekdays: 1800 422 737
- Canteen — for 12 to 25 year olds affected by cancer, their own or a family member's: 1800 945 215
- Palliative Care Australia — directory of palliative care services near you: palliativecare.org.au
- Lifeline — 24/7, for any kind of distress, at any hour the services above are closed: 13 11 14
Palliative care is not the same as giving up on treatment, and it is not only for the last weeks of life. It is symptom and comfort care that can run alongside active treatment, including a clinical trial.
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of support and crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention.
Voxsanity is not a counselling or medical service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Contact this trial
Phone: 86-21-64041990
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival in CF arm; 3-years Overall Survival Rate in CF arm
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.